
# COMT × Fisetin: Research Evaluation and Experimental Proposal

**Principal Investigator Report**
**Date:** 09_July_2026 02:50 AM PDT
**Subject:** Evaluation of fisetin as a COMT modulator and its dual senolytic–neuromodulatory potential for longevity

---

## Summary

[[Fisetin]] (3,3′,4′,7-tetrahydroxyflavone) is a natural [[Flavonoid]] with demonstrated [[Senolytic|senolytic]], neuroprotective, anti-inflammatory, and antioxidant properties. It is also a validated inhibitor of [[COMT]] (catechol-O-methyltransferase), with [[IC50]] values in the low micromolar range (2.6–5.8 µM) against human liver COMT. This dual activity—simultaneously clearing [[Senescent Cells]] and modulating [[Catecholamines|catecholamine]]/[[Dopamine]] metabolism—creates a pharmacologically interesting but mechanistically complex intersection. This report evaluates the empirical basis for COMT modulation by fisetin, its implications for longevity research, and proposes a rigorous experimental plan.

> [!IMPORTANT]
> **Key Finding**
> Fisetin is not merely a passive COMT inhibitor. It is a **substrate-inhibitor** that is itself O-methylated by COMT, generating the active metabolite [[Geraldol]] (3′,4′,7-trihydroxy-3′-methoxyflavone). This means COMT activity directly shapes fisetin's pharmacokinetic fate, and fisetin's COMT inhibition is substrate-competitive—raising dose- and genotype-dependent complexity that has been inadequately explored in longevity studies.

---

## Molecular Profile: Fisetin as a COMT Substrate and Inhibitor

### Direct COMT Inhibition Evidence

| Parameter | Value | Source |
|-----------|-------|--------|
| IC₅₀ (COMT, rat liver, [[Dopamine]] as substrate) | 5.78 µM | Paudel et al. 2019 (PMID: 31258092) |
| IC₅₀ (COMT, human liver cytosol, 2-OH-[[Estrogen\|E₂]] methylation) | 3.3–4.5 µM | Zhu et al. 2004 (Drug Metab Dispos 32:497) |
| IC₅₀ (COMT, human liver cytosol, 4-OH-[[Estrogen\|E₂]] methylation) | 2.6–4.2 µM | Zhu et al. 2004 |
| Inhibition type | Mixed (competitive + noncompetitive) | Zhu et al. 2004 |
| [[Monoamine oxidase\|MAO-A]] inhibition (IC₅₀) | 7.33 µM | Paudel et al. 2019 |
| MAO-B inhibition | Not significant | Paudel et al. 2019 |

### Mechanism: Fisetin as a COMT Substrate

Fisetin contains a catechol moiety (3′,4′-dihydroxy B-ring) that serves as a substrate for COMT-mediated O-methylation. This was directly demonstrated by Poor et al. (2016, Biomed Pharmacother 83:998–1005):

- Fisetin is metabolized by COMT to [[Geraldol]] (3′-O-methylfisetin)
- This metabolic activation is concentration-dependent
- The process consumes [[SAMe]] and generates [[SAH]] (S-adenosylhomocysteine), a potent feedback inhibitor of COMT
- At low concentrations: fisetin acts primarily as a substrate (undergoes methylation)
- At higher concentrations: fisetin acts as a competitive inhibitor (occupies the active site without being efficiently methylated)

> [!WARNING]
> **Critical Implication**
> Fisetin's COMT inhibition is not a simple on/off pharmacological effect. It is concentration-dependent, genotype-sensitive, and generates an active metabolite (geraldol) that may itself have distinct biological activity. Any study examining fisetin's neurological or longevity effects must account for this metabolic interplay.

### Structure–Activity Relationship Context

Fisetin belongs to the [[Flavonol]] class with a catechol B-ring. Comparing with known [[COMT Inhibitors]]:

| Compound | COMT IC₅₀ (µM) | Mechanism |
|----------|----------------|-----------|
| [[Quercetin]] | 0.9–1.5 | Competitive (catechol substrate) |
| Fisetin | 2.6–5.8 | Mixed (competitive + noncompetitive) |
| (+)-[[Catechin]] | 0.86 | Competitive |
| [[EGCG]] | 0.04–0.07 | Tight-binding inhibitor |
| Entacapone (clinical) | ~0.23 | Competitive (nitrocatechol) |
| Tolcapone (clinical) | ~0.048 | Competitive (nitrocatechol) |

Fisetin's COMT inhibition potency is moderate—~10–50× weaker than clinical COMT inhibitors but within the range achievable through dietary supplementation or nutraceutical dosing (particularly with enhanced bioavailability formulations).

---

## Multi-Pharmacology: Senolytic and COMT-Modulatory Axes

### Senolytic Activity (Primary Longevity Mechanism)

Fisetin's senolytic properties are well-validated:

- **[[Bcl-2]]/[[Bcl-xL]] inhibition:** Fisetin binds the hydrophobic groove of anti-apoptotic Bcl-2 family proteins, sensitizing senescent cells to [[Apoptosis]]. Computational modeling (PMC11914956) confirms favorable binding energies: Bcl-2:fisetin = −22.2 to −35.1 kcal/mol depending on ionization state; Bcl-xL selectivity is pharmacologically preferred.
- **[[PI3K]]-[[Akt]] pathway inhibition:** Fisetin inhibits PI3K, reducing Akt phosphorylation and suppressing Bcl-2/Bcl-xL expression in senescent endothelial cells (Ji et al. 2025, PMID: 38789909).
- **In vivo efficacy:** Intermittent dosing (100 mg/kg/day, 1 week on/2 weeks off) reduces senescent cell burden in skeletal muscle, aorta, and adipose tissue of aged mice. Cdkn1a ([[p21]]) expression reduced ~46% (Murray et al. 2025).
- **[[SASP]] suppression:** Fisetin reduces circulating SASP factors including [[CXCL12]], partially rescuing age-related endothelial dysfunction (PMID: 40894771).
- **Lifespan extension:** Oral fisetin in wild-type mice late in life extended median and maximum lifespan (Yousefzadeh et al. 2018).

### COMT Inhibition: Therapeutic Potential and Risks

#### Potential Benefits:

- **[[Dopamine]] augmentation in [[Prefrontal Cortex\|prefrontal cortex]]:** COMT is the primary dopamine-degrading enzyme in the PFC. Moderate COMT inhibition could enhance working memory and executive function, particularly in individuals with the Val/Val (fast COMT) genotype. This is relevant because aging is associated with declining prefrontal dopamine tone.

- **[[Estrogen]] metabolism modulation:** COMT methylates catechol estrogens (2-OH-E₂, 4-OH-E₂) to less genotoxic methoxyestrogens. Inhibition by fisetin could shift estrogen metabolism, with complex tissue-dependent consequences. 2-Methoxyestradiol (2-MeO-E₂) is anti-angiogenic and pro-apoptotic; reduced formation could theoretically be disadvantageous in cancer contexts, but the net effect depends on tissue estrogen levels and local COMT expression.

- **[[Levodopa\|L-DOPA]] synergy (if applicable):** In [[Parkinson's Disease]] models, COMT inhibition by fisetin could potentiate L-DOPA efficacy—analogous to entacapone but with additional senolytic benefits.

#### Potential Risks:

- **[[Catecholamines|Catecholamine]] accumulation:** Excessive COMT inhibition could elevate [[Epinephrine]]/[[Norepinephrine]], particularly under oxidative stress conditions, potentially increasing autoxidation to [[Aminochromes|aminochromes]] (adrenochrome, dopaminochrome). This is a mechanistic concern, not an empirical observation at fisetin doses.

- **Catechol [[Estrogen]] accumulation:** Inhibition of COMT-mediated O-methylation of catechol estrogens could increase formation of quinone intermediates that damage DNA—potentially relevant for estrogen-receptor-positive tissues.

- **[[SAMe]]/[[SAH]] imbalance:** Fisetin is a COMT substrate; its methylation consumes SAMe and generates SAH. Chronic high-dose fisetin could shift the SAMe:SAH ratio, affecting global methylation capacity. This is particularly relevant for individuals with slow COMT (Met/Met) who already have altered methylation dynamics.

- **Genotype-dependent effects:** Slow COMT individuals (Met/Met, ~20–30% of Europeans) already have elevated synaptic dopamine. Adding fisetin-mediated COMT inhibition could push dopamine levels into a supraoptimal range for PFC function (inverted-U relationship), potentially impairing rather than enhancing cognition.

---

## Pharmacokinetic Considerations

### Bioavailability Challenge

Fisetin has notoriously poor oral [[Bioavailability|bioavailability]]:

- **Free fisetin t₁/₂ in serum:** 2.7 min (IV), <90 min (oral) in rats
- **Human Cmax (unformulated, 1000 mg oral):** ~10 ng/mL (~33 nM) — far below the IC₅₀ for COMT inhibition (2.6–5.8 µM)
- **Metabolites:** Rapid conjugation to sulfates/glucuronides; O-methylation to [[Geraldol]]

### Enhanced Bioavailability Formulations

| Formulation | Bioavailability enhancement | Cmax achieved |
|-------------|---------------------------|---------------|
| FF-20 (FENUMAT hydrogel) | 26.9-fold vs. unformulated | 238.2 ng/mL (~780 nM) |
| S-[[SNEDDS]] colon-targeted | 4.4–6.9-fold | Rat model |
| [[Nanoparticles\|Nanosuspension]] | Improved (rat data) | ~225 nm particles |

> [!NOTE]
> **Bioavailability vs. COMT Threshold**
> Even with the best current formulations, peak plasma fisetin concentrations (~0.8 µM) remain below the IC₅₀ for COMT inhibition. This suggests that **dietary fisetin supplementation at standard nutraceutical doses (100–500 mg) is unlikely to produce meaningful systemic COMT inhibition in peripheral tissues.** However:
> - **Local concentrations in the GI tract** may transiently exceed the IC₅₀, potentially affecting enteric COMT
> - **Brain penetration** may achieve higher local concentrations due to fisetin's lipophilicity (log P = 3.2) and reported [[Blood-Brain Barrier|BBB]] crossing
> - **Intermittent high-dose protocols** (as used in senolytic trials: 20 mg/kg/day for 5 days) may transiently reach inhibitory concentrations
> - **[[Geraldol]]** (the COMT-generated metabolite) may have distinct COMT-inhibitory properties that have not been characterized

### Active Clinical Trials

- **NCT06796374:** Comparison of fisetin kinetics in young vs. old adults (100 mg and 1000 mg doses, ± quercetin). This trial will provide critical data on age-dependent fisetin pharmacokinetics and the effect of co-administered COMT inhibitor quercetin on fisetin metabolism.
- Multiple Phase I/II senolytic trials (fisetin for frailty, osteoarthritis, diabetic kidney disease) — pharmacokinetic secondary endpoints pending.

---

## Hypotheses for Investigation

### COMT inhibition is therapeutically relevant at senolytic doses
**Rationale:** While standard supplementation may not reach COMT-inhibitory plasma concentrations, the intermittent high-dose senolytic protocols (20 mg/kg × 5 days in humans) may achieve transient inhibitory levels, particularly in brain tissue.
**Test:** Measure plasma and CSF fisetin/geraldol levels and COMT activity (via dopamine/methoxytyramine ratios) in aged subjects before and after fisetin senolytic dosing.

### COMT genotype modifies fisetin's senolytic and cognitive effects
**Rationale:** Val/Val individuals (fast COMT) have lower baseline dopamine; fisetin-mediated COMT inhibition could enhance cognition. Met/Met individuals (slow COMT) may experience adverse neurochemical effects from further COMT suppression.
**Test:** Stratify fisetin clinical trial participants by COMT [[Val158Met]] genotype; measure cognitive endpoints and senescence markers as co-primary outcomes.

### COMT inhibition contributes to fisetin's neuroprotective effects
**Rationale:** If fisetin inhibits brain COMT, this could augment dopaminergic tone and enhance ERK/CREB/BDNF signaling—pathways already implicated in fisetin's neuroprotection.
**Test:** In COMT knockout mice or with selective COMT inhibitors, determine whether fisetin's neuroprotective effects are attenuated or enhanced. Use PET imaging with [¹⁸F]-FMT to measure COMT activity in vivo.

### [[Geraldol]] has distinct bioactivity
**Rationale:** Geraldol is generated by COMT-mediated methylation of fisetin. It has been detected in plasma at levels exceeding free fisetin. Its COMT-inhibitory and senolytic properties are uncharacterized.
**Test:** Synthesize geraldol; evaluate COMT inhibition (IC₅₀, Ki, mechanism), Bcl-2/Bcl-xL binding (docking, SPR), senolytic activity in senescent cell models, and in vivo pharmacokinetics.

---

## Proposed Experimental Plan

### Phase One: In Vitro Characterization

#### Fisetin–COMT Binding and Kinetics
- **Enzyme:** Recombinant human S-COMT and MB-COMT
- **Substrates:** [[Dopamine]], [[Norepinephrine]], [[Epinephrine]], 2-OH-[[Estrogen|E₂]], 4-OH-E₂
- **Methods:** Radiochemical assay with [³H]-[[SAMe]]; [[Michaelis-Menten Kinetics|Michaelis-Menten]] and Lineweaver-Burk kinetic analysis
- **Endpoints:** Ki, IC₅₀, mechanism (competitive/noncompetitive/mixed), substrate selectivity
- **Controls:** Entacapone (positive), [[Quercetin]] (structural analog)
- **Novel addition:** Measure fisetin O-methylation rate ([[Geraldol]] formation) by LC-MS/MS at each inhibitor concentration to quantify the substrate-inhibitor partition

#### Dual Senolytic–COMT Activity
- **Cell models:** Senescent IMR-90 fibroblasts ([[Etoposide|etoposide]]-induced), primary senescent [[Endothelial Cells|endothelial cells]], senescent preadipocytes
- **Co-assays:** SA-β-Gal, [[p21]]/[[p16]] Western, SASP ELISA panel ([[IL-6]], [[IL-8]], [[CXCL12]], [[MMP-3]]), apoptosis ([[Caspase-3]]/7), COMT activity (dopamine/methoxytyramine ratio in cell lysates)
- **Dose-response:** 0.1–50 µM fisetin (to bracket the IC₅₀ for COMT)
- **Key question:** Does fisetin's senolytic activity correlate with or depend on its COMT inhibition?

#### Computational Modeling
- **Molecular docking:** Fisetin, geraldol, and quercetin into COMT crystal structures (PDB: 3BWM, 4A76) and Bcl-2/Bcl-xL (PDB: 4LVT, 2XA0)
- **MD simulations:** 100–500 ns trajectories for fisetin–COMT and fisetin–Bcl-2 complexes; free energy perturbation (FEP) calculations
- **Network pharmacology:** Map fisetin's multi-target profile across COMT, Bcl-2, Bcl-xL, [[PI3K]], LOX, MAO, [[NF-κB]], [[NRF2]], [[AMPK]], [[mTOR]] using STRING and KEGG pathway analysis
- **QSAR:** Predict COMT inhibition from fisetin derivatives with modified B-ring catechol (to test whether the catechol is essential for COMT activity vs. senolytic activity)

### Phase Two: In Vivo Proof-of-Concept

#### Fisetin Pharmacokinetics and COMT Activity in Aged Mice
- **Animals:** Young (6 mo) and old (24 mo) C57BL/6J mice
- **Dosing:** Fisetin 20 mg/kg/day × 5 days (senolytic protocol) or 100 mg/kg intermittent (as in Murray et al. 2025)
- **Sampling:** Plasma, brain, liver, adipose at 1, 4, 8, 24 h post-last dose
- **Analytes:** Fisetin, geraldol, fisetin-glucuronide, fisetin-sulfate (LC-MS/MS); dopamine, DOPAC, 3-MT, HVA (brain microdialysis or tissue homogenate); SAH, SAMe (LC-MS/MS)
- **COMT activity:** Ex vivo COMT assay in liver and brain cytosol
- **Key endpoints:** Correlate brain fisetin/geraldol levels with COMT inhibition magnitude and dopamine metabolite ratios

#### COMT Genotype–Fisetin Interaction
- **Animals:** COMT [[Val158Met]] knock-in mice (available from Jackson Labs) or wild-type vs. COMT heterozygous knockout
- **Design:** 2×2 factorial (genotype × fisetin treatment)
- **Endpoints:** [[Frailty]] index, grip strength, rotarod, novel object recognition, Y-maze; senescence markers ([[p16]], [[p21]], SA-β-Gal) in brain, muscle, adipose; COMT activity in brain
- **Critical test:** Does fisetin benefit Met/Met (slow COMT) mice less or more than Val/Val (fast COMT) mice?

#### Fisetin in COMT Knockout Mice
- **Rationale:** If COMT inhibition contributes to fisetin's effects, the magnitude of benefit should differ in COMT-null background
- **Design:** Wild-type vs. COMT⁻/⁻ mice, young and aged, treated with vehicle or fisetin
- **Endpoints:** Lifespan (if powered), healthspan markers, senescence burden, brain neurotransmitter profiles, cognitive testing

### Phase Three: Clinical Translation

#### Pharmacogenomic Clinical Trial (Phase II)
- **Design:** Randomized, double-blind, placebo-controlled
- **Population:** Adults ≥60 years, enriched for Val/Val and Met/Met COMT genotypes
- **Intervention:** Fisetin (1000 mg/day × 5 days, repeated monthly) or matched placebo × 12 months
- **Primary endpoints:** [[Epigenetic Aging|Epigenetic age]] (GrimAge, DunedinPACE), frailty index
- **Secondary endpoints:** Cognitive function (MoCA, digit span), plasma SASP panel, COMT activity (plasma dopamine/methoxytyramine), fisetin/geraldol PK, safety (liver function, [[Homocysteine]])
- **Exploratory:** Single-cell transcriptomics of peripheral immune cells (senescence markers), brain MRI (if feasible)

---

## Risk Assessment and Mitigation

| Risk | Likelihood | Impact | Mitigation |
|------|-----------|--------|------------|
| Fisetin at senolytic doses does not reach COMT-inhibitory brain levels | Medium | High | Measure brain fisetin directly in Phase 2; consider intranasal delivery |
| COMT inhibition by fisetin causes catecholamine excess in slow COMT individuals | Low–Medium | Medium | Genotype-stratify all clinical trials; exclude Met/Met from high-dose arms initially |
| SAMe depletion from chronic fisetin methylation | Low | Medium | Monitor SAMe:SAH ratio in Phase 2 and 3; supplement methyl donors if needed |
| Geraldol has unfavorable activity profile | Unknown | Medium | Characterize geraldol independently (Experiment 1.3) |
| Fisetin's senolytic and COMT effects are pharmacologically independent (no synergy) | Medium | Low | This is actually informative; would decouple the two mechanisms for optimization |

---

## Literature Gaps Requiring Immediate Attention

- **No direct measurement of brain COMT activity modulation by fisetin in vivo.** All existing COMT inhibition data is in vitro. This is the single most critical gap.

- **[[Geraldol]] pharmacology is essentially uncharacterized.** The COMT-generated metabolite of fisetin has no published data on COMT inhibition, senolytic activity, or receptor binding.

- **No clinical trial has stratified fisetin outcomes by COMT genotype.** Given that COMT activity varies 3–4 fold across genotypes, this is a glaring omission.

- **[[SAMe]]/[[SAH]] dynamics with chronic fisetin supplementation are unstudied.** Since fisetin is a COMT substrate, chronic dosing could affect systemic methylation capacity—critical for epigenetic maintenance in aging.

- **Fisetin's effect on catechol [[Estrogen]] metabolism in vivo is unknown.** The in vitro inhibition of COMT-mediated catechol estrogen O-methylation (Zhu et al. 2004) has not been followed up with in vivo studies. This has implications for hormone-sensitive cancer risk.

- **Dose–response for COMT inhibition vs. senolytic activity has not been established.** At what concentration does fisetin meaningfully inhibit COMT? Is this below, at, or above the senolytic threshold? The two activities may operate at different concentration ranges.

---

## Conclusion

Fisetin is a legitimate [[COMT Inhibitors|COMT inhibitor]] and COMT substrate with moderate potency (IC₅₀ ~3–6 µM). Its pharmacological profile is uniquely bifurcated:

- **At low concentrations (nM):** Primarily acts as a substrate for COMT (undergoes O-methylation to [[Geraldol]])
- **At intermediate concentrations (low µM):** Mixed-type COMT inhibition with [[Monoamine oxidase|MAO-A]] inhibition
- **At higher concentrations (mid µM):** Senolytic activity via [[Bcl-2]]/[[Bcl-xL]] inhibition

The overlap between COMT-inhibitory and senolytic concentration ranges is uncertain and likely cell-type and tissue-dependent. Current evidence does not support the conclusion that dietary fisetin supplementation produces meaningful COMT inhibition in vivo, but the hypothesis has not been adequately tested, particularly with enhanced bioavailability formulations or at senolytic dosing protocols.

> [!TIP]
> **Bottom Line**
> Fisetin is worth investigating as a dual COMT modulator and [[Senolytic|senolytic]], but the COMT axis has been almost entirely neglected in the longevity literature. A systematic pharmacogenomic investigation—beginning with mouse studies stratified by COMT genotype and measuring brain COMT activity directly—is essential before any claims about COMT-related mechanisms of fisetin's healthspan benefits can be made.

---

## References (Selected)

- Paudel YN et al. (2019). Evaluation of Selected Natural Compounds as Dual Inhibitors of COMT and MAO. PMID: 31258092
- Zhu BT et al. (2004). Strong Inhibitory Effects of Tea Catechins and Bioflavonoids on COMT-Mediated O-Methylation of Catechol Estrogens. Drug Metab Dispos 32:497.
- Poor M et al. (2016). Structure related effects of flavonoid aglycones on cell cycle progression of HepG2 cells: metabolic activation of fisetin and quercetin by COMT. Biomed Pharmacother 83:998–1005.
- Yousefzadeh MJ et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36:18–28.
- Murray K et al. (2025). Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging. Aging Cell. PMID: 40093023
- Mahoney S et al. (2025). Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12. PMID: 40894771
- Ji XM et al. (2025). Fisetin Clears Senescent Cells Through the Pi3k-Akt-Bcl-2/Bcl-xl Pathway. Pharm Res. PMID: 38789909
- PMC11914956. Fisetin as a Blueprint for Senotherapeutic Agents – Elucidating Geroprotective and Senolytic Properties with Molecular Modeling.
- Krishnakumar IM et al. (2022). Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci 11:e72.
- Zhu BT et al. (2010). O-Methylation of Catechol Estrogens by Human Placental COMT: Interindividual Differences. Drug Metab Dispos.

---

## Documents

- [[_document_ - Fisetin—In Search of Better Bioavailability—From Macro to Nano Modifications A Review|Fisetin Bioavailability Review]]
  - Covers nanodelivery strategies overcoming fisetin's poor oral bioavailability; relevant to achieving COMT-inhibitory plasma concentrations.
- [[_document_ - COMT How to Optimize Your Supplements for Your COMT Genotype|COMT Genotype Supplement Optimization]]
  - Discusses COMT genotype-dependent supplement interactions including fisetin as a COMT inhibitor.
- [[_document_ - Fisetin is a senotherapeutic that extends health and lifespan|Fisetin Senotherapeutic & Lifespan]]
  - Primary efficacy study establishing fisetin as the most potent flavonoid senolytic; lifespan extension in aged mice.

## Connections

- [[COMT]]: Primary enzymatic target; fisetin is a validated substrate-inhibitor with mixed-type kinetics
- [[Fisetin]]: Parent compound with dual senolytic–COMT pharmacology
- [[Geraldol]]: Active COMT-generated metabolite of fisetin; uncharacterized pharmacology
- [[Val158Met]]: Key genotype modifier determining COMT activity and fisetin response
- [[Dopamine]]: Primary COMT substrate in PFC; fisetin-mediated inhibition could augment dopaminergic tone
- [[Bcl-2]] / [[Bcl-xL]]: Anti-apoptotic proteins targeted by fisetin's senolytic mechanism
- [[SASP]]: Senescence-associated secretory phenotype suppressed by fisetin
- [[SAMe]] / [[SAH]]: Methylation cofactors consumed/generated during fisetin O-methylation
- [[Estrogen]]: Catechol estrogen metabolism modulated by COMT inhibition
- [[PI3K]]-[[Akt]]: Signaling pathway inhibited by fisetin in senescent cells
- [[AMPK]] / [[mTOR]] / [[NRF2]]: Longevity pathways in fisetin's network pharmacology profile
- [[Senolytic]]: Fisetin's primary therapeutic classification
- [[Parkinson's Disease]]: Potential L-DOPA synergy with COMT inhibition
- [[Epigenetic Aging]]: Primary endpoint in proposed clinical trial

## Linking Summary

- New links added: [[COMT]], [[Fisetin]], [[Geraldol]], [[Val158Met]], [[Dopamine]], [[Catecholamines]], [[Epinephrine]], [[Norepinephrine]], [[Bcl-2]], [[Bcl-xL]], [[PI3K]], [[Akt]], [[SASP]], [[CXCL12]], [[IL-6]], [[IL-8]], [[MMP-3]], [[SAMe]], [[SAH]], [[Estrogen]], [[Flavonoid]], [[Flavonol]], [[Quercetin]], [[Catechin]], [[EGCG]], [[AMPK]], [[mTOR]], [[NRF2]], [[NF-κB]], [[p21]], [[p16]], [[Caspase-3]], [[Etoposide]], [[Endothelial Cells]], [[Frailty]], [[Epigenetic Aging]], [[Homocysteine]], [[Blood-Brain Barrier]], [[SNEDDS]], [[Nanoparticles]], [[Bioavailability]], [[Michaelis-Menten Kinetics]], [[MMP-3]], [[Parkinson's Disease]], [[Levodopa]], [[Monoamine oxidase]], [[Aminochromes]], [[IC50]], [[Senolytic]], [[Senescent Cells]], [[Apoptosis]], [[Prefrontal Cortex]], [[Catechol-O-methyltransferase]]
- Suggested new entity notes to create: [[Bcl-xL]], [[Entacapone]], [[Tolcapone]], [[Opicapone]], [[Senolytic Dosing Protocol]]
- Strong connections to strengthen:
  - [[Fisetin]] ↔ [[COMT]] — substrate-inhibitor relationship with concentration-dependent pharmacology
  - [[Fisetin]] ↔ [[Geraldol]] — metabolic parent-product relationship; geraldol pharmacology uncharacterized
  - [[COMT]] ↔ [[Val158Met]] ↔ [[Fisetin]] — genotype-stratified response hypothesis
  - [[Fisetin]] ↔ [[Bcl-2]] / [[Bcl-xL]] — senolytic mechanism via anti-apoptotic protein binding
  - [[SAMe]] ↔ [[SAH]] ↔ [[Fisetin]] — methylation cofactor dynamics during fisetin metabolism
